The approval of a fast-acting, short-term medication in the United States for postpartum depression has generated anticipation among Canadian maternal health experts and advocates. They hope that people in Canada will soon have access to the same treatment. Zuranolone, marketed as Zurzuvae, is the first oral drug specifically designed for severe depression after childbirth. Clinical trials have shown that relief starts on day three of a two-week regimen, which is a significant improvement compared to standard antidepressants that can take up to three months to show mood improvement. However, the drug manufacturers, Biogen and Sage Therapeutics, have not yet applied for approval from Health Canada.
The attention given to maternal health and mortality related to childbirth has increased in recent years, but gaps still exist in supporting those coping with postpartum depression. Currently, only one drug, Zulresso, targets postpartum depression and is approved in the U.S., but it is administered intravenously in a medical facility for 60 hours at a high cost of US$34,000. Zuranolone offers a more accessible option, and its price has not been determined yet.
Zuranolone received approval in the U.S. after demonstrating significant improvement in symptoms such as suicidal ideation, anxiety, and insomnia in a randomized controlled clinical trial. The study involved nearly 200 participants who were given zuranolone or a placebo pill for two weeks. The improvement in symptoms lasted for 45 days after the first dose. Previous trials have also shown positive results with different dosages.
Postpartum depression affects a significant number of individuals, with a 2019 Statistics Canada report showing that almost one-quarter of people who gave birth experienced symptoms consistent with postpartum depression or an anxiety disorder. The availability of zuranolone in Canada would provide a much-needed treatment option for these individuals.
Zuranolone targets the brain’s GABA receptors, which play a crucial role in stress and mood regulation. By compensating for reduced levels of a naturally occurring neurosteroid during pregnancy, it offers relief from the deep despair of postpartum depression. One individual, Carole Dagher, shares her experience of struggling with postpartum depression and the challenges she faced in finding an effective treatment.
Dr. Diane Francoeur, CEO of the Society of Obstetricians and Gynaecologists of Canada, emphasizes the need for zuranolone to be available in Canada as soon as possible, as depression can have severe consequences for women. She also highlights the importance of combining medication with psychotherapy for severe cases of postpartum depression.
Daisy Singla, a clinical psychologist, and associate professor of psychiatry at the University of Toronto, acknowledges the promising nature of zuranolone and its potential benefits, but also stresses the importance of talk therapy as part of treatment. Singla is leading a study comparing the effectiveness of different therapy providers, including mental health specialists and laypeople, in treating postpartum depression.
In conclusion, the approval and availability of zuranolone in Canada would provide a much-needed treatment option for individuals suffering from postpartum depression. Its fast-acting relief and unique oral formulation make it a promising solution for those in need. However, it is essential to combine medication with psychotherapy for effective treatment, highlighting the need for accessible and affordable therapy options.
Denial of responsibility! VigourTimes is an automatic aggregator of Global media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, and all materials to their authors. For any complaint, please reach us at – [email protected]. We will take necessary action within 24 hours.
